Quest PharmaTech announces sale of non-core assets
Quest disengages completely from China
Continuing the Company's effort to sell its non-core assets, Quest also announced the sale of its AntiCort rights back to Samaritan Pharmaceuticals, Inc. for gross proceeds of $50,000 U.S. and 50,000 common shares of Samaritan. The sale is part of an arrangement whereby Quest has agreed to discontinue its statement of claim that was brought against Samaritan in March, 2006.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.